About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 49
Unknown
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
This study is a multicenter, open-label, phase II clinical study in subjects with chronic hepatitis B (CHB), to characterize the safety, tolerability, pharmacokinetic profile and…
NCT04568265
·
Guangzhou, Guangdong and 3 others
Completed
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
This is a follow-up of Study A3L10 (NCT00315055) Immunogenicity * To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-HB-PRP\~T or…
NCT00619502
·
Ankara
Not yet recruiting
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B)…
NCT06786429
Completed
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP\~T vaccine is consistent.
NCT00404651
·
Estado de México and 5 others
Completed
The Psychoneuroimmunology of Insomnia
Chronic insomnia affects approximately 8-9% of the population. The prevalence of this disorder rises dramatically across the lifespan, especially so in women.
NCT00680771
·
Rochester, New York
Completed
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
To demonstrate that DTaP-IPV-HB-PRP\~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of…
NCT00313911
·
Mexico City and 1 other
Completed
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP\~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after…
NCT00315055
·
Ankara
Completed
A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines
The purpose of this study is to generate an exploratory training set of data and to identify predictive biomarkers (a measurable biological response that predicts something) of…
NCT02032160
·
Guildford, Surrey
Completed
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV- Hep B-PRT\~T fully liquid combined hexavalent vaccine (Hexaxim™) administered at 6, 10…
NCT01948193
·
Ludhiana, Punjab and 1 other
Completed
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people.
NCT07784452
·
Lahore, Punjab Province
Completed
Pentavalent DTaP-Hep B-IPV
The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the…
NCT00133445
·
Torrance, California
Completed
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722) and booster vaccination in Study A3L27 (NCT01444781).
NCT01983540
·
Cali and 1 other
Completed
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
The purpose of the study is to provide immunogenicity and safety data of the investigational hexavalent vaccine when it is given concomitantly (the same day at separate injection…
NCT00401531
·
Bangkok and 1 other
Terminated
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
This is a Phase 2, randomized, open-label exploratory study that will examine the antiviral efficacy, safety, and tolerability of Response guided treatment (RGT) with GS-5885 +…
NCT01384383
·
Los Angeles, California and 54 others
Completed
Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients
This is a preliminary trial of a Hepatitis B vaccine (Heplisav-B) in medically immunosuppressed patients.
NCT04199715
·
Dallas, Texas
Completed
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
This is a follow-up of Study A3L11 (NCT00404651).
NCT00654901
·
Estado de México and 3 others
Completed
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to…
NCT00362336
·
Soweto, Johannesburg and 1 other
Completed
Safety and Tolerability of TG1050: A Dose-finding Study
Methodology: This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection.
NCT02428400
·
Edmonton, Alberta and 11 others
Completed
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae…
NCT00441012
Completed
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
This study will determine whether participants who receive the vaccine V419 at 2, 3, 4, and 12 months of age have an acceptable immune response to the vaccine.
NCT01341639
Back
1
2
3
1 / 3
Next
Data from
ClinicalTrials.gov
Terms
